Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian after recent acute coronary syndrome
PACTR202312651823009Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS), myocardial infarction (MI) and unstable angina comparing Milvexian with Matching placebo (2 arms). Started Mar 2023; status: recruiting.
02
Drugs
milvexian
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable angina
Beyond the preview
Go deeper on PACTR202312651823009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202312651823009.